|
|
Blood, 1 August 2008, Vol. 112, No. 3, pp. 516-518.
Prepublished online as a Blood First Edition Paper on May 20, 2008; DOI 10.1182/blood-2008-02-141580.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Brief Report
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Constantine S. Tam1,
Hagop Kantarjian1,
Guillermo Garcia-Manero1,
Gautam Borthakur1,
Susan O'Brien1,
Farhad Ravandi1,
Jenny Shan1, and
Jorge Cortes1
1 Leukemia Department, University of Texas M. D. Anderson Cancer Center, Houston
To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, patients achieving a major cytogenetic response (12MMCyR) had a significant survival advantage over patients in minor cytogenetic response or complete hematologic response, with a projected one-year survival of 97% and 84% respectively (P = .02). Projected 1-year progression to hematologic failure, accelerated phase, or blast phase was also significantly different (3% vs 17%, P = .003). Early cytogenetic response was strongly predictive of achievement of 12MMCyR, with less than 10% of patients showing no cytogenetic response at 3 to 6 months eventually attaining the target of 12MMCyR. These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. J. Garg, H. Kantarjian, S. O'Brien, A. Quintas-Cardama, S. Faderl, Z. Estrov, and J. Cortes
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Blood,
November 12, 2009;
114(20):
4361 - 4368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, J. E. Cortes, and H. M. Kantarjian
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Mayo Clin. Proc.,
February 1, 2009;
84(2):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cortes
When Imatinib Fails, What Else Is There?
ASCO Educational Book,
January 1, 2009;
2009(1):
402 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O'Hare and M. W. Deininger
Toward a Cure For Chronic Myeloid Leukemia
Clin. Cancer Res.,
December 15, 2008;
14(24):
7971 - 7974.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Marin, D. Milojkovic, E. Olavarria, J. S. Khorashad, H. de Lavallade, A. G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, et al.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
Blood,
December 1, 2008;
112(12):
4437 - 4444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford, R. Lawrence, L. Fletcher, C. Field, Z. Rudzki, and T. Hughes
The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
331 - 331.
[Abstract]
[Full Text]
|
|
|
|
|
